The Rose Lab focuses on advances in image-guided radiotherapy for prostate cancer, particularly the use of novel MRI sequence know as restriction spectrum imaging (RSI) as a biomarker of treatment response. Preliminary results indicate strong correlation between RSI changes and PSA response as well the feasibility of focal dose-escalation to the residual RSI nodule.

A second research focus is on the impact of competing risks of non-cancer mortality on the benefit of effective cancer therapies. Dr. Rose (along with Dr. Loren Mell) has developed a competing risk model that incorporates the risk of cancer and non-cancer events into a risk score. They are in the process of testing their model on randomized clinical trial data and large observational databases in order to better model the benefits of treatment as a function of competing risks.